P43 In vitro activity of cefiderocol and comparators against Gram-negative pathogens: ARTEMIS study in the UK

OBJECTIVES: Cefiderocol (CFDC) is a novel siderophore cephalosporin approved in Europe for the treatment of infections caused by aerobic Gram-negative (GN) bacteria in adults with limited treatment options. The aim of the ARTEMIS study was to evaluate the in vitro activity of CFDC and comparators ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Wareham, D., Attwood, M., Casey, A. L., Coyne, M., Hughes, D., Lister, M., Nahl, J., Perry, J. D., Henriksen, A. Santerre, Longshaw, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Posters Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039995/
http://dx.doi.org/10.1093/jacamr/dlac004.042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039995/
http://dx.doi.org/10.1093/jacamr/dlac004.042

Ejemplares similares